Brind.

Arcellx underperformed the S&P 500 market so far this year.

1 report, 1 independent Updated Aug 8
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Arcellx underperformed the S&P 500 market so far this year.

Who's involved

What this event is mainly about
Arcellx

Keep exploring

The entities involved

  • Arcellx

    Biotechnology Company

    Nothing else this week.

Coverage

Newest first; wire copies grouped
  • ZacksArcellx, Inc. (ACLX) Reports Q2 Loss, Misses Revenue Estimates Arcellx, Inc. (ACLX) came out with a quarterly loss of $0.94 per share versus the Zacks Consensus Estimate of a loss of $1.03. This comp